Business Wire

Corindus, A Siemens Healthineers Company, Announces Study Results Demonstrating Safety and Effectiveness of CorPath® GRX Neurovascular System

Share

Corindus, A Siemens Healthineers Company and a leading developer of precision vascular robotics, announced today it presented the results of a first-of-its-kind study demonstrating the safety and effectiveness of robotic-assisted neurovascular aneurysm embolization using the CorPath GRX Neurovascular System. The data represents a milestone in the company’s commitment to extending precision robotics into neurovascular treatment.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220907006221/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

CorPath GRX Neurovascular System (Photo: Business Wire)

The prospective, single-arm, international, multi-center, non-inferiority study is the world’s first trial on robotic-assisted neurovascular aneurysm embolization. Principal Investigator Michel Piotin, MD, PhD, Head of the Interventional Neuroradiology Department at the Rothschild Foundation Hospital in Paris, presented the results as part of the AI & New Innovations session at the European Society of Minimally Invasive Neurological Therapy (ESMINT) Congress in Nice, France. Key findings of the study showed:

  • The CorPath GRX Neurovascular System demonstrated 94 percent technical success. It achieved the primary effectiveness goal, which was defined as successful completion of the robotic-assisted endovascular procedure absent of any unplanned conversion to a manual procedure.
  • The CorPath GRX Neurovascular System demonstrated 95.7 percent clinical success. It achieved the primary safety goal, defined as patients treated without intra- and periprocedural adverse events, including target aneurysmal rupture, vessel perforation or dissection, and thromboembolic event with neurological decline within 24 hours post-procedure or hospital discharge, whichever occurred first.
  • 64.5 percent of subjects achieved Class I status, meaning complete obliteration of the aneurysm, on the Raymond-Roy Occlusion Classification (RROC), the standard for evaluating aneurysm occlusion.
  • 78.2 percent of subjects showed no clinical symptoms post-procedure, achieving a 0 on the Modified Rankin Scale (mRS) for Neurologic Disability. The remaining 21.8 percent of subjects had an mRS of 1 or 2.

“Neurovascular intervention demands extreme precision to achieve optimal clinical outcomes,” said Dr. Piotin. “The results of the study show the CorPath GRX System helps physicians move efficiently within tortuous and unstable vessels. I am honored to have participated in a groundbreaking study that may lead to an entirely new treatment paradigm in neurovascular care.”

The study included 117 patients from 10 clinical sites in six different countries. It also included a wide range of aneurysms, representing a diverse collection of cases with different locations, sizes and morphology characteristics. The healthcare facilities that treated the trial participants will follow them for 180 days to monitor extended, long-term outcomes.

“The work of our clinical partners on this study marks an early step toward truly transformative change in neurovascular intervention,” said Dr. Raymond Turner, Chief Medical Officer, Neuroendovascular at Corindus. “By incorporating robotic platforms in this space, we are paving the way for remote interventional procedures in the future that will connect patients to specialized interventionalists for treatment, regardless of location. Validating clinical evidence, such as this study, will serve as the foundation for that transformation.”

The CorPath GRX System is the first FDA-cleared and CE Marked medical device for percutaneous coronary and vascular procedures. It earned CE Mark for neurovascular procedures, and healthcare facilities outside of the U.S. currently utilize the platform for neurovascular interventions. The company is currently pursuing additional regulatory clearances for the neurovascular indication.

To learn more about CorPath GRX, please visit www.corindus.com.

ABOUT CORINDUS

Corindus, A Siemens Healthineers Company, is a global technology leader in robotic-assisted vascular interventions. The Company’s CorPath® platform is a medical device to bring robotic precision to percutaneous coronary and vascular procedures. CorPath GRX is the second-generation robotic-assisted technology offering enhancements to the platform by adding important key upgrades that increase precision, improve workflow, and extend the capabilities and range of procedures that can be performed robotically. We are focused on developing innovative robotic solutions to revolutionize treatment of emergent conditions by providing specialized and timely medical care to patients around the world. For additional information, visit www.corindus.com , and follow @CorindusInc.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:
Matter Health for Corindus
Jill Gross
+1 978-518-4258
corindus@matternow.com

Siemens Healthineers, North America
Jeffrey Bell
+1 484-868-8346
Jeffrey.t.bell@siemens-healthineers.com

Siemens Healthineers, Europe
Kathrin Palder
+49 173-3645319
kathrin.palder@siemens-healthineers.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Aizon Launches New AI-powered eBR Light Solution to Enhance Manufacturing Productivity in Collaboration with Euroapi18.9.2024 19:00:00 EEST | Press release

Aizon, an Artificial Intelligence (AI) SaaS provider dedicated to transforming pharmaceutical manufacturing operations, is launching a new product called Aizon Execute, an innovative eBR (Electronic Batch Record) software product, developed in collaboration with Euroapi, a leading global API manufacturer. This collaboration was born out of the need to digitize operations towards more data-driven manufacturing - focusing on the essential user needs while avoiding the heavy lift currently associated with going paperless in manufacturing. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240918037613/en/ Aizon Execute is a modern, user-centric, lightweight product designed to adapt to small-scale productions and highly flexible plants like chemical API CDMOs - and has the potential to become the true backbone of digital transformation journeys. Aizon Execute light eBR is designed to facilitate the rapid transition from paper-based

Headline Closes $865 Million to Invest in Growth-Stage Tech Companies18.9.2024 18:53:00 EEST | Press release

Headline today announced Headline Global Growth IV with $865M1 of capital committed to the strategy to support companies at their Growth inflection points, Series B and beyond. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240918812241/en/ Headline's Global Growth Equity Team (Photo: Business Wire) The Global Growth strategy has three distinct advantages: a diverse and experienced team, extensive geographic coverage, and advanced in-house built technology for sourcing (Searchlight) and analytics (DeepDive). Led by seasoned Growth investor Shalini Rao, the Growth team is committed to identifying and nurturing "Paradiesvögel"—tenacious technology founders poised for global success. Recent team additions to Headline Global Growth include Nancy Xiao, Trevor Neff, Reda Bensaid, Jake Horwitz and Austin Hack, all of whom will work out of Headline’s San Francisco and European offices. Global Growth IV represents the evolution of gr

New Garmin G5000 Avionics Upgrade Now Available for Cessna Citation XLS Aircraft at Textron Aviation Service Centers18.9.2024 18:00:00 EEST | Press release

Textron Aviation today announced customers can now upgrade their Cessna Citation XLS+ and Citation XLS Gen2 aircraft with the Garmin G5000 integrated flight deck following Garmin’s receipt of FAA supplemental type certification (STC) for the avionics upgrade. Customers can have the upgrade installed at selected domestic Textron Aviation Service Centers to add significant technological advances and new capabilities to their aircraft. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240918046690/en/ New Garmin G5000 avionics upgrade now available for Cessna Citation XLS aircraft at Textron Aviation Service Centers. (Photo: Garmin, Textron Aviation) Beechcraft, Cessna and Hawker customers receive factory-direct support, maintenance and modifications by Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, through a global network of service and part centers, mobile service units and 24/7 1CALL AOG support. “The G5000 avionic

ProAmpac Brings Fiberization and Sustainable Packaging Innovation to FACHPACK 202418.9.2024 17:45:00 EEST | Press release

ProAmpac, a leader in flexible packaging and material science, will showcase its latest sustainable packaging solutions at FACHPACK 2024 from September 24-26 in Nuremberg, Germany. At stand 5-126, ProAmpac will present advanced offerings such as ProActive Recyclable® FibreSculpt, ProActive Intelligence® Moisture Protect MP-1000, and the ProActive Recyclable® RP-1050, alongside its RAP Packaging line of fiber-based food-to-go solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240918028305/en/ FibreSculpt (Photo: Business Wire) “We invite attendees to explore ProAmpac’s innovative solutions driving the fiberization of packaging,” said Alex Baumgartner, president of ProAmpac’s European division. “From our MP-1000 technology, which transforms moisture control in powdered beverages and nutraceuticals, to our fiber-based food-to-go packaging, these advancements meet the growing demand for sustainable, high-performance packa

Takeda Commits Over $32 Million in Five New Global Corporate Social Responsibility Partnerships to Further Drive Health Impact in 93 Countries18.9.2024 17:00:00 EEST | Press release

Takeda (TOKYO:4502/NYSE: TAK) today committed JPY4.6 billion (Approx. USD 32 million) to five new Global Corporate Social Responsibility (CSR) partners as part of the company’s ongoing commitment to improving health systems resiliency in low and middle-income countries around the world. This commitment demonstrates Takeda’s focus on tackling systemic disparities and supporting local leadership in strengthening health infrastructure, empowering health workforce, and increasing local knowledge and capacity to improve equitable and sustainable healthcare access and delivery. By 2030, these new collaborations are anticipated to extend Takeda’s impact to 27 million people across 93 countries, raising the total contributions from Takeda’s Global CSR Program to over JPY 28.8 billion (Approx. USD 199.1 million) across 34 significant partnerships since it began in 2016. The five new partners were selected by more than 22,000 Takeda employees across 80 countries and regions through a company-wid

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye